PUBLISHER: QYResearch | PRODUCT CODE: 1867550
PUBLISHER: QYResearch | PRODUCT CODE: 1867550
The global market for Blood Collection Tubes for Liquid Biopsy was estimated to be worth US$ 120 million in 2024 and is forecast to a readjusted size of US$ 426 million by 2031 with a CAGR of 18.6% during the forecast period 2025-2031.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Blood Collection Tubes for Liquid Biopsy cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Blood Collection Tubes for Liquid Biopsy are specialized in vitro diagnostic consumables designed to collect and stabilize whole blood samples for the preservation of circulating biomarkers such as cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), cfRNA, and circulating tumor cells (CTCs). Unlike conventional blood tubes, these products inhibit cell lysis and enzymatic degradation post-collection, ensuring high sample integrity critical for non-invasive early cancer detection, treatment monitoring, and therapy selection. Common types include cfDNA stabilizing EDTA tubes and CTC capture tubes, which are compatible with platforms like NGS, high-throughput PCR, and droplet digital PCR (ddPCR).
The rapid advancement of global precision oncology is the key driver of the liquid biopsy blood collection tube market. Annual reports from companies such as Illumina, Guardant Health, and Exact Sciences reveal an increasing reliance on high-quality blood samples, boosting demand for premium sample collection consumables. Simultaneously, government initiatives such as the U.S. "Cancer Moonshot" and China's "Thousand Counties Project" are pushing early cancer screening into public health systems, making blood collection tubes strategic consumables. Emerging use cases in chronic disease monitoring, prenatal testing, and at-home sampling are also expanding market potential.
Despite robust growth, the market faces several hurdles including high regulatory barriers, long validation cycles for stability, and strict requirements for platform compatibility. Reports from Biocept and Natera indicate that products must comply with FDA and CE-IVDR standards, increasing development costs. The presence of low-cost alternatives intensifies price-based competition. In addition, maintaining sample integrity during logistics-especially under cold-chain requirements-poses challenges for adoption in rural hospitals and remote sampling scenarios.
Liquid biopsy tubes are currently used primarily in cancer screening and companion diagnostics, but their application is expanding to multi-cancer early detection (MCED), minimal residual disease (MRD) testing, and AI-powered diagnostics. Guardant Health's 2024 annual report notes collaborations with hospitals and pharmaceutical companies to build large-scale biobanks, indicating a shift in customer base from academic to commercial use including CROs, CDMOs, and biopharma firms. With the rise of at-home sampling and decentralized diagnostics, the industry is moving toward portable, ambient-stable tube designs to meet diversified market needs.
This report aims to provide a comprehensive presentation of the global market for Blood Collection Tubes for Liquid Biopsy, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Blood Collection Tubes for Liquid Biopsy by region & country, by Type, and by Application.
The Blood Collection Tubes for Liquid Biopsy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Collection Tubes for Liquid Biopsy.
Market Segmentation
By Company
Segment by Type
Segment by Application
By Region
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Blood Collection Tubes for Liquid Biopsy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Blood Collection Tubes for Liquid Biopsy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Blood Collection Tubes for Liquid Biopsy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.